Protara Therapeutics Inc. (TARA) will be presenting new data from an interim analysis of its ongoing ADVANCED-2 trial at the 25th Annual Meeting of the Society of Urologic Oncology on December 5, 2024.
ADVANCED-2 is an ongoing phase II trial of the company's drug candidate TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com